CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Respirerx Pharmaceuticals Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Respirerx Pharmaceuticals Inc
126 Valley Rd Ste C
Phone: (201) 444-4947p:201 444-4947 GLEN ROCK, NJ  07452-1796  United States Ticker: CORXCORX
Business Summary
RespireRx Pharmaceuticals Inc. develops treatments to combat disorders caused by disruption of neuronal signaling. The Company is developing treatment options that address conditions, such as obstructive sleep apnea (OSA), attention deficit hyperactivity disorder, epilepsy, acute and chronic pain, including inflammatory and neuropathic pain, and recovery from spinal cord injury (SCI), which are conditions that affect millions of people, as well as certain orphan disorders such as GRIA. It also considers developing treatment options for other conditions based on results of preclinical and clinical studies to date. The Company has two business units. ResolutionRx unit holds its pharmaceutical cannabinoids platform, and is developing compounds that target the body’s endocannabinoid system, and in particular, the re-purposing of dronabinol for the treatment of OSA. EndeavourRx is its neuromodulators platform, which is made up of two programs: AMPAkines program and GABAkines program.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
-Yes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202312/31/2022YesYes---

Industries
SIC Code Description
2834 Pharmaceutical preparations
8731 Commercial physical and biological research

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board, Interim President, Interim Chief Executive Officer, Chief Scientif Arnold S.Lippa 76 1/31/2022 3/22/2013
Chief Financial Officer, Senior Vice President, Treasurer, Secretary, Director Jeff E.Margolis 65 2/17/2017 3/22/2013
Senior Vice President - Pre-Clinical Product Development DavidDickason 9/15/2020 9/15/2020
3 additional Officers and Directors records available in full report.

Business Names
Business Name
CORX
Pier Pharmaceuticals, Inc.
ResolutionRx Ltd incorporated in Australia
RSPI
RSPID

General Information
Number of Employees: 2 (As of 12/31/2022)
Outstanding Shares: 365,418,647 (As of 11/27/2023)
Shareholders: 4,000
Stock Exchange: OTC
Federal Tax Id: 330303583
Fax Number: (302) 652-6760
Email Address: ir@cortexpharm.com


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, April 19, 2024